IRLAB is granted additional patent for drug candidate mesdopetam
IRLAB is granted additional patent for drug candidate mesdopetam that expands its patent protection
Gothenburg, Sweden, September 4, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the process of its preparation. The patent that has now been granted extends the already strong patent protection for mesdopetam, the company’s most advanced project.
“The already strong patent protection for mesdopetam is now expanded with a patent, EP3976581B1, which protects the active pharmaceutical ingredient of mesdopetam used in clinical development. With the extended protection, there is potential to extend market exclusivity for mesdopetam right up to the early 2040s, which is incredibly positive for the value of mesdopetam,” said Kristina Torfgård, CEO of IRLAB.
Mesdopetam has a vast clinical potential for unmet medical needs in Parkinson’s disease. The drug candidate is intended to treat people with Parkinson’s who develop levodopa induced dyskinesias (PD-LIDs), which is more than 30 percent of all people living with Parkinson’s. This equates to more than 1.5 million affected individuals in the eight major markets worldwide.
Mesdopetam has previously been granted a family of substance patents in all major markets worldwide. The newly approved patent covers a salt of mesdopetam which is used in the formulations in the ongoing clinical development. The patent expires in 2040. With the potential grant of a supplementary protection certificate (SPC) exclusivity can reach into the early 2040s.
Latest Posts
- Iranian Crude Loading Resumes At Kharg Island After US Blockade Lifted: Bloomberg Report
June 21, 2026 | Breaking News, Politics, World - Switzerland Peace Deal; Iran Negotiators Left Iran To Discuss Peace Deal With US
June 21, 2026 | Breaking News, Politics, World - Historic Naranag Temple Reopens for Devotees, Tourists After Security Review; LG Ofice Announces
June 20, 2026 | Breaking News, Jammu Kashmir - 59 People Hospitalised In Maharashtra After Suspected Food Poisoning
June 20, 2026 | Breaking News, India - Bihar Court Grants ‘No Coercive Action’ Order To Faisal Khan Alias ‘Khan Sir’ Until Next Hearing
June 20, 2026 | Breaking News, Courts & Law, India - Israeli Strikes In Southern Lebanon, 5 Killed
June 20, 2026 | Breaking News, Politics, World - India Secures the Vice-Presidency of the Financial Action Task Force (FATF), Vivek Aggarwal Appointed
June 20, 2026 | Breaking News, Politics, World - Urged Israel to Agree To Ceasefire Deal With Hezbollah says, President Donald Trump
June 20, 2026 | Breaking News, Politics, World - Big Setback To Google As Nobel Prize Winner John Jumper Quits Google DeepMind For Anthropic
June 20, 2026 | Breaking News, Technology - Israel and Hezbollah Have Agreed To Ceasefire: Report
June 19, 2026 | Breaking News, Politics, World